Therefore, measurable CK-BB activity is rarely seen, and in the serum of normal adults it is very low and below the detection limit of most methods. When tissue containing CK-BB is diseased or damaged, increased CK-BB activity can appear in the serum. CK-BB has been described as a marker for adenocarcinoma of the prostate, breast, ovary, colon, other adenocarcinomas of the gastrointestinal tract, and for small-cell anaplastic carcinoma of the lung (11). One of the most important causes of CK-BB in serum is brain damage in caseswith concomitant breakdown of the bloodbrain barrier (8).
(8). The half life of CK-BB in human serum was estimated to be 5 h by Harwood et al. (9), 1 h by Vladutiu et al. (10).
Therefore, measurable CK-BB activity is rarely seen, and in the serum of normal adults it is very low and below the detection limit of most methods. When tissue containing CK-BB is diseased or damaged, increased CK-BB activity can appear in the serum. CK-BB has been described as a marker for adenocarcinoma of the prostate, breast, ovary, colon, other adenocarcinomas of the gastrointestinal tract, and for small-cell anaplastic carcinoma of the lung (11). One of the most important causes of CK-BB in serum is brain damage in caseswith concomitant breakdown of the bloodbrain barrier (8).
An intact blood-brain barrier seems to block the penetration of CK-BB activity into the serum effectively. Bayer et al. (12) measured 118 U of CK-BB per liter in the cerebrospinal fluid of a patient suffering from brain damage without being able to detect CK-BB in the serum. On the other hand, a few cases have been reported of serum CK-BB activity, apparently of brain origin, in serum (13,14). In some as-yetundelineated cases, therefore, the blood-brain barrier seems to break down.
The cancer patients in our study exhibited some damage to their blood-brain barrier, as judged from the amount of contrast dye present on their CAT scan. All intra-axial brain tumors with enhancement must have some disruption of the blood-brain barrier if the dye is to be seen within the brain parenchyma. We have no logical explanation for the small amount of CK-BB activity in our cancer patients' serum as compared with those patients with contusions and infarcts.
We saw no significant correlation between CK-BB as measured with the Impres-BB kit and the volume of damaged brain tissue in patients with either brain contusions, infarcts, or primary or metastatic brain cancer. We attribute this lack of correlation to an intact blood-brain barrier (which is more likely in infarcts and contusions), rapid elimination or inactivation of CK-BB, or some combination of these. Statistically, we also note that with an n value equal to ours En= 71(20 were controls)], we have a power of 0.80 for detecting an r of 0.34 with a two-tailed t-test with 0.05 significance level. That is, we had a reasonable chance of detecting a correlation as small as 0.34.
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More work is needed to clarify the conditions and the transport mechanisms that can lead to the leakage of brain isoenzymes into the blood (8). Our study shows that CK-BB is a poor index of actual damaged brain tissue.
We thank International Immunoassay
Laboratories for the Impres-BB reagents, and Margaret Darnell for her assistance in obtaining specimens. Several sensitive colorimetric assays have been developed for metabolites since Trinder (1) described the coupled reaction catalyzed by glucose oxidase (EC 1.1.3.4) and peroxidase (EC 1.11.1.7) for the assay of glucose, with phenol and 4-aininophenazone as the chromogenic system. Assays for cholesterol (2), uric acid (3), phospholipids (4), triglycerides (5), and creatinine (6) have been reported in which hydrogen peroxide produced by metabolite-specific oxidase is detected by mean of peroxidase and an appropriate chromogenic system. These methods are popular because they combine the use of a single reagent mixture (except for creatinine) with measurements in the visible region of the spectrum.
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Urea, another important metabolite, is currently assayed as a strong index to renal function. Thus its measurement is a common procedure, and different methods are available. Among them, those involving urea conversion to ammonia by urease (EC 3.5.1.5) are extensively used; the ammonia so produced is assayed spectrophotometrically by the colorimetric method of Berthelot (7, 8) or with the glutamate dehydrogenase reaction, either by a kinetic or an equilibrium assay (9, 10). However, none of these methods combine the advantages of the above-mentioned methods for other metabolites, so we developed a new assay for urea that involves the following reaction sequence: ureaee (EC 3.5.1.5)
Urea+H20
C02+2NH3 six-position cell changer (Kontron, Zurich, Switzerland) for optimization studies. Comparison methods: we used the ultraviolet ureaseglutamate dehydrogenase candidate Reference Method previously described (11).
Mix 5 ,uL of sample or urea standard and 1 mL of reagent and allow the mixture to stand for 15 miii at 37 #{176}C; then measure the absorbance at 500 nm vs a reagent blank. Urea concentrations in unknown samples are determined by comparison with a standard curve constructed by using data on dilutions of the stock urea standard solution. The color is stable for lh at 37 #{176}C. 
Resufts

quinone-monoimine dye + 2 H20
The broad absorbance maximum of the quinone-monoimine dye near 500 nm is proportional to the urea concentration. The present method is the first reported colorimetric assay for urea that is based on hydrogen peroxide measurement and that can be performed by using all reagents in a single mixture.
Materials and Methods
Apparatus
We used a Model SEA ifi spectrophotometer (Helena Laboratories, Beaumont, TX 77704) and a Model Uvikon 860 double-beam spectrophotometer equipped with a Peltier Reagents Procedure Figure 1 shows the absorbance spectra of the quinonemonoimine dye. Because the reaction product absorbs maximally at 500 nm, we used this wavelength routinely. However, when urea concentrations exceeded 30 mmol/L, A,,1,,exceeded the linearity range of current spectrophotometers (2 A). We solved this problem by measuring the absorbance at 550 nm for both the standard and such samples. In this way we were able to measure urea concentrations of 40 mmolJL without sample dilution. Figure 2 shows the time course of color development monitored continously for urea standards, serum sample, and reagent blank. The reaction is consistently complete in 15 mm at 37#{176}C, and the absorbance remains constant for a further 30 mm at the same temperature. A ,,,,, for the reagent blank varied from 0.06 to 0.11, depending principal- ly on the concentration of ammonium ions contaminating the different batches of glutamate used to prepare the reagent. We assessedthe linearity of reagent response, both at 500 nm and 550 nm, using urea standards with concentrations ranging from 0 to 50 mmol/L. When the absorbance change at 500 nm was plotted vs urea concentration, the relation was linear up to 40 mmol/L, with the following coefficients for the linear regression equation: slope + SD = 0.063 + 0.001; intercept + SD = 0.009 + 0.015 (r = 1.00; S = 0.03). The absorbance for the highest standard in the linear range (40 mmol/L) decreased from 2.50 at 500 nm to 1.71 at 550 nm. Table 1 shows the analytical recovery of urea added to six different human sera. The mean recovery was 99.3%.
We assessed within-run precision, using three human sera. Portions of these samples were stored frozen and one portion was assayed daily for 20 days; Table 2 summarizes the results.
Results of linear regression of serum urea data measured in 106 samples by both the present method and the candidate Reference Method are presented in Figure 3 .
We evaluated analytical interference by endogenous metabolites, common anticoagulants, and drugs according to the IFCC guidelines of the Expert Panel on Drug Effect in Clinical Chemistry (12). Table 3 lists those substances without effects on the present assay; Figure 4 illustrates the effects of compounds that interfered significantly at high concentration.
DiscussIon
The present method for the enzymic colorimetric assay of urea by use of glutamune synthetase allows the coupling of urea hydrolysis by urease with the pyruvate and hydrogen peroxide-producing reactions catalyzed respectively by pyruvate kinase and pyruvate oxidase. We initially used glutamine synthetase extracted from sheep brain (13), but later changed to the more readily obtainable and welldescribed enzyme purified from E. coli (14). 
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For reagent optimization, we selected a saturating concentration of substrate and coenzymes and explored a pH range covering the reported optimum pH of each enzyme, to minimize the incubation time that would afford a stable absorbance.
An acceptable compromise between assay time and cost determined the enzyme activities used in the assay. Under the conditions chosen, the rate-limiting step of the whole reaction sequence is the pyruvate oxidase-catalyzed reaction.
A major problem encountered in developing the procedure was to minimize assay sensitivity in order to ensure a sufficient linearity of response vs urea concentration. The low sample/reagent volume ratio (1/201) and the choice of phenol in the chromogenic system allowed us to assay directly samples with urea concentrations as high as 40 mmolJL. In this case, A exceeded 2.0, but a further decrease of sensitivity was achieved by shifting the measuring wavelength to 550 nm. In the present method, there is potential interference by pyruvate, because this compound is a part of the reaction sequence. However, the usual endogenous pyruvate concentration is <0.1 mmoIJL (15) and would only account for about 1% of urea concentrations falling within the normal reference interval. Moreover, the instability of pyruvate in lactate dehydrogenase-containing samples such as human serum (15) obviates the need for routine use of a sample blank. Among other possible interferents, including commonly used drugs at concentrations five to 10 times their therapeutic concentration in blood, we found results significantly depressed only by gentisic acid and, to a lesser extent, by bilirubin and ascorbic acid. Quantification of these interferences showed they are nonsignificant for gentisic acid and ascorbic acid at therapeutic concentration whereas biirubin at 300 anol/L lowered results by about 0.4 mmoljL. Use of potassium ferrocyanide would probably decrease this slight interference of bilirubin, as has been previously shown for other Trinder reactions (6, 16). We conclude that this new colorimetric method is a possible alternative to the ultraviolet method, allowing manual assay of urea to be performed with a single reagent and in commonly used colorimeters.
